Prodifferentiation Activity of Novel Vitamin D2 Analogs PRI-1916 and PRI-1917 and Their Combinations with a Plant Polyphenol in Acute Myeloid Leukemia Cells
Open Access
- 5 July 2016
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (7) , 1068
Abstract
1α,25-dihydroxyvitamin D3 (1,25D3) is a powerful differentiation inducer for acute myeloid leukemia (AML) cells. However, 1,25D3 doses required for differentiation of AML cells may cause lethal hypercalcemia in vivo. There is evidence that vitamin D2 is less toxic than vitamin D3 in animals. Here, we determined the differentiation effects of novel analogs of 1α,25-dihydroxyvitamin D2 (1,25D2), PRI-1916 and PRI-1917, in which the extended side chains of their previously reported precursors (PRI-1906 and PRI-1907, respectively) underwent further 24Z (24-cis) modification. Using four human AML cell lines representing different stages of myeloid maturation (KG-1a, HL60, U937, and MOLM-13), we found that the potency of PRI-1916 was slightly higher or equal to that of PRI-1906 while PRI-1917 was significantly less potent than PRI-1907. We also demonstrated that 1,25D2 was a less effective differentiation agent than 1,25D3 in these cell lines. Irrespective of their differentiation potency, all the vitamin D2 derivatives tested were less potent than 1,25D3 in transactivating the DR3-type vitamin D response elements. However, similar to 1,25D3, both 1,25D2 and its analogs could strongly cooperate with the plant polyphenol carnosic acid in inducing cell differentiation and inhibition of G1–S cell cycle transition. These results indicate that the 24Z modification has contrasting effects on the differentiation ability of PRI-1906 and PRI-1907 and that the addition of a plant polyphenol could result in a similar extent of cell differentiation induced by different vitamin D compounds. The enhanced antileukemic effects of the tested combinations may constitute the basis for the development of novel approaches for differentiation therapy of AML.Keywords
Funding Information
- Israel Science Foundation (635/11)
This publication has 46 references indexed in Scilit:
- Cell-Type-Specific Effects of Silibinin on Vitamin D-Induced Differentiation of Acute Myeloid Leukemia Cells Are Associated with Differential Modulation of RXRα LevelsLeukemia Research and Treatment, 2012
- The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3Best Practice & Research Clinical Endocrinology & Metabolism, 2011
- The Nrf2 transcription factor is a positive regulator of myeloid differentiation of acute myeloid leukemia cellsCancer Biology & Therapy, 2011
- Silibinin can induce differentiation as well as enhance vitamin D3‐induced differentiation of human AML cells ex vivo and regulates the levels of differentiation‐related transcription factorsHematological Oncology, 2009
- Vitamin D and differentiation in cancerCritical Reviews in Clinical Laboratory Sciences, 2009
- High‐performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic studyBiomedical Chromatography, 2009
- Synergistic Antileukemic Activity of Carnosic Acid-Rich Rosemary Extract and the 19-nor Gemini Vitamin D Analogue in a Mouse Model of Systemic Acute Myeloid LeukemiaOncology, 2008
- MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapyBlood, 2005
- Enhancement by other compounds of the anti-cancer activity of vitamin D3 and its analogsExperimental Cell Research, 2004
- Lack of p53 expression in human myeloid leukemias is not due to mutations in transcriptional regulatory regions of the geneLeukemia, 2002